Antimicrobial resistance remains high in Europe, says new report
28 Feb 2018 --- Bacteria from humans and animals continue to show resistance to antimicrobials, according to a new report published by the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC).
The report highlights some emerging issues and confirms antimicrobial resistance (AMR) – which reduces the effectiveness of treatment options – as one of the biggest threats to public health.
Vytenis Andriukaitis, European Commissioner for Health and Food Safety, has reaffirmed his commitment to tackling AMR: “Levels of antimicrobial resistance still differ significantly from one EU country to another. To win the fight, we need to join our efforts and implement stringent policies on the use of antibiotics across sectors,” he said.
“It is vital that we all renew our commitment to fight antimicrobial resistance by focusing on the key areas set out in the EU One Health Action Plan against antimicrobial resistance.”
Among the new findings, based on data from 2016, are the detection of resistance to carbapenems in poultry, an antibiotic which is not authorized for use in animals, and of ESBL-producing Salmonella Kentucky with high resistance to ciprofloxacin in humans, which was reported for the first time in four countries.
“We are concerned to see that Salmonella and Campylobacter bacteria in humans show high levels of antimicrobial resistance. The fact that we keep detecting multidrug-resistant bacteria means that the situation is not improving,” said Mike Catchpole, ECDC’s chief scientist.
“We need to investigate the origins and prevent the spread of highly resistant strains, such as ESBL-producing Salmonella Kentucky.”
“The detection of resistance to carbapenems in poultry and linezolid in methicillin-resistant Staphylococcus aureus in pigs is alarming because these antibiotics are used in humans to treat serious infections,” adds Marta Hugas, EFSA’s chief scientist. “It is important that risk managers follow-up on these findings.”
Main findings for humans
One out of four Salmonella infections in humans is caused by Salmonella bacteria that show resistance to three or more antimicrobials commonly used in human and animal medicine. The proportion is significantly higher in S. Kentucky and S. Infantis (76.3 and 39.4 percent respectively).
For the first time, ESBL-producing S. Kentucky with high resistance to ciprofloxacin was detected in four countries. This type of bacteria cannot be treated with critically important antibiotics.
Campylobacter bacteria, which cause the most common foodborne disease in the EU, show high resistance to widely used antibiotics (ciprofloxacin resistance 54.6 percent in C. jejuni and 63.8 percent in C. coli; tetracycline resistance 42.8 percent in C. jejuni and 64.8 percent in C. coli).
The levels of resistance increased in two of the three analyzed antibiotics (ciprofloxacin and tetracycline), but combined resistance to the critically important antimicrobials is stable and overall low (0.6 percent in C. jejuni and 8.0 percent in C. coli).
In some countries, however, at least one in three C. coli infections were multidrug-resistant to important antibiotics, leaving very few treatment options for severe infections.
Animals and foods
Resistance to carbapenem antibiotics was detected at a very low level in poultry and chicken meat in two member states (fifteen E. coli bacterial isolates). Carbapenems are used to treat serious infections in humans and are not authorized for use in animals.
Two livestock-associated methicillin-resistant Staphylococcus aureus bacterial isolates found in pigs were reported to be linezolid-resistant. Linezolid is one of the last-resort antimicrobials for the treatment of infections caused by highly resistant MRSA.
Combined clinical resistance to critically important antimicrobials was observed at low to very low levels of Salmonella (0.2 percent), Campylobacter (1 percent) and E. coli (1 percent) in poultry.
Resistance to colistin was observed at low levels (2 percent) in Salmonella and E. coli in poultry.
Prevalence of ESBL-producing E. coli in poultry varies markedly between member states, from low (less than 10 percent) to extremely high levels (more than 70 percent).
Bacteria that produce ESBL enzymes show multi-drug resistance to β-lactam antibiotics – a class of broad-spectrum antibiotics that includes penicillin derivatives, cephalosporins and carbapenems.
This is the first time that the presence of extended-spectrum beta-lactamase (ESBL)-producing E. coli was monitored in poultry and poultry meat.
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
